Drug intelligence / Profile preview

interferon or glatiramer acetate

Development stage: Unknown
Lead developer: Teva Pharmaceutical Industries
Administration: Injection

Overview

"Interferon or glatiramer acetate" refers to two distinct medication options used for treating multiple sclerosis. These are Interferon Beta and Glatiramer Acetate. Interferon Beta works by modulating the immune system, reducing inflammation and T-cell activity. Glatiramer Acetate is an immunomodulatory agent that shifts T-cell populations to a more regulatory phenotype. Both are considered first-line treatments for relapsing-remitting multiple sclerosis.

Targets

IFNAR (Immune system modulation via type I interferon receptor)MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on interferon or glatiramer acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon or glatiramer acetate.

Explore the full profile